不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性弥漫大 B 细胞淋巴瘤的新药
英文原题：Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
查看英文原题
Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
复发/难治性（R/R）弥漫大B细胞淋巴瘤（DLBCL）患者，如果不适合或在大剂量化疗联合自体干细胞移植或CAR-T 细胞治疗后复发，预后较差。几种新型药物，polatuzumab vedotin、tafasitamab、loncastuximab tesirine和selinexor，已获批，为这一难以治疗的人群提供了新机会。研究正在评估这些药物与化疗和其他新兴疗法的联合应用。此外，我们对DLBCL生物学、遗传学和免疫微环境理解的进步，使得能够识别出新的治疗靶点，如Ikaros和Aiolos、IRAK4、MALT1和CD47，多种药物正在进行临床试验。在本章中，我们回顾了支持使用已获批药物的更新数据，并讨论了针对R/R DLBCL患者的其他新兴新型疗法。
展开英文摘要原文
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), ineligible for or relapsing after autologous stem-cell transplant or chimeric antigen-receptor T-cell therapies have poor outcomes. Several novel agents, polatuzumab vedotin, tafasitamab, loncastuximab tesirine, and selinexor, have been approved and offer new opportunities for this difficult to treat population. Studies are evaluating combination of these agents with chemotherapy and other emerging therapies.
Additionally, advances in our understanding of DLBCL biology, genetics, and immune microenvironment have allowed for the identification of new therapeutic targets like Ikaros and Aiolos, IRAK4, MALT1, and CD47 with several agents in ongoing clinical trials. In this chapter we review updated data supporting the use of the approved agents and discuss other emerging novel therapies for patients with R/R DLBCL.
论文信息
- 作者
- Varma G、Goldstein J、Advani RH
- 第一作者单位
- Division of Hematology and Medical Oncology, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.United States
- 通讯作者单位
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.United States
- 文献类型
- 综述
- 期刊
- Hematological oncology2023 Jun
- 原文标识
- PubMed 37294966 · DOI 10.1002/hon.3143